Press release
Antiviral Drugs Market Report Forecasts Impressive Growth by 2024
With the significant increase in the incidence of viral infections, the global antiviral drugs market is witnessing a substantial rise in its size and valuation. The increasing prevalence of chronic infections, such as HIV/AIDS and hepatitis B, which require long-term treatment, is also adding considerably to the growth of this market.
Read the Comprehensive Overview of Antiviral Drugs Market: http://www.transparencymarketresearch.com/antiviral-drugs-market.html
Going forward, the strong focus of drugmakers on research and developments, resulting in innovation and advancements in drugs and therapies, together with the rising reports of newer viral infectious diseases, is likely to boost the market for antiviral drugs to great extents over the forthcoming years. The availability of low cost treatments and the advancements in healthcare facilities in developing regions are also projected to impact this market positively in the near future.
The opportunity in the global market for antiviral drugs was worth US$48.3 bn in 2015. Researchers anticipate it to increase to US$82.9 bn by 2024, rising at a CAGR of 6.40% between 2016 and 2024.
North America to Continue as Market Leader
Among all the regional markets for antiviral drugs, namely, Asia pacific, North America, Latin America, the Middle East and Africa, and Europe, the leading position has been acquired by North America. With a share of more than 50%, the North America market for antiviral drugs stood strong in 2015 and is expected to remain dominant over the next few years. The increasing pool of patients suffering from viral infections and the high cost of new drugs are likely to boost this regional market remarkably over the years to come.
Europe stood second in the global market for antiviral drugs in 2015. Analysts predict this regional market will retain its position in the coming years, thanks to the large number of patients undergoing antiretroviral treatments, fueled by the increasing preference for novel drugs among consumers. The rising level of awareness, better diagnostic facilities, continued launches of effective drugs, and the presence of favorable reimbursement policies for the high-cost treatments are also expected to drive the Europe market for antiviral drugs over the next few years.
Among other regional antiviral drugs markets, Asia Pacific, followed by the Middle East and Africa, is anticipated to present most promising opportunities for the growth of this market. The key factors attributed for this are the soaring prevalence of HIV/AIDS and hepatitis, high-paced spreading of various infectious viral diseases, such as influenza, and the increasing preference for better healthcare facilities. The rising penetration of drugs for novel viral infections, such as Ebola and Zika, together with improved as well as affordable second version drugs, is anticipated to drive both the markets, i.e., Asia Pacific and the Middle East and Africa, over the forthcoming years.
Demand for Antiviral Drugs to Remain High from HIV Infection Segment
Antiviral drugs are mainly utilized in the treatment of hepatitis virus infection, HIV infection, and respiratory virus infection. With the alarming rise in the reports of HIV infection, the demand for antiviral drugs from this segment has been higher than others. Thanks to the invention of new drugs for HIV, which convert fatal illness into chronic pathology thereby increasing the lifespan of the patient, favorable reimbursement policies, and the availability of affordable drugs in emerging countries, the segment is likely to remain driving high demand for these drugs over the years to come.
Request for the Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=21083
Teva Pharmaceutical Industries Ltd., Mylan N.V., Merck & Co. Inc., Johnson & Johnson, GlaxoSmithKline Plc, Gilead Sciences Inc., F. Hoffmann-La Roche Ltd., Cipla Inc., Bristol-Myers Squibb Co., and AbbVie Inc. are some of the leading antiviral drug makers across the world.
About TMR
Transparency Market Research (TMR) is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Antiviral Drugs Market Report Forecasts Impressive Growth by 2024 here
News-ID: 594517 • Views: …
More Releases from TMR - Research Reports
Pulmonary Drugs Market is Expected to Reach US$ 28,082.1 Million by the End of 2 …
According to the research report, the global pulmonary drugs market is expected to be worth US$ 28,082.1 mn by the end of 2024 as compared to US$ 48,039.7 mn in 2015. Analysts calculate that the global market will plummet at a CAGR of -6.3% during the forecast period of 2016 and 2024. The market will thrive as the demand for combination drugs is anticipated to remain on the rise during…
North America Ventricular Assist Device Market is rising to a valuation of US$ 1 …
According to TMR, the opportunity in the North America market for VADs, which stood at US$0.4 bn in 2015, is likely to expand at a healthy CAGR of 9.20% between 2016 and 2024 and increase to US$1.07 bn by the end of the forecast period. The destination therapy (DT) segment has been reporting a greater application of VADs than the other two indication segments. It is expected to remain the…
Dental Membrane and Bone Graft Substitutes Market to rise to US$ 922.6 Million b …
Transparency Market Research notes that innovation and expansion into emerging regions have served these companies well in strengthening their hold in the dental membrane and bone graft substitutes market. For instance, Switzerland-based Geistlich Pharma AG - a global manufacturer and supplier of dental products and devices - expanded its operations in Sydney, Australia and New Delhi, India in 2016.
The global dental membrane and bone graft substitutes market is expected to…
Human Vaccines Market is Estimated to Reach US$ 72.5 Billion by 2024
The global human vaccines market was valued at US$28.3 bn in 2015 and is estimated to reach US$72.5 bn by 2024, registering an 11.2% CAGR during the forecast period.
By age group, pediatric vaccines accounted for a 57.5% share in the global human vaccines market in 2015. Adult vaccines, on the other hand, are expected to expand at a 13.2% CAGR from 2016 to 2024. Based on product, the pneumococcal segment…
More Releases for Antiviral
Antiviral Drugs Market Size, Report 2022-2030
Acumen Research and Consulting has announced the addition of the "Antiviral Drugs Market" report to their offering.
The Antiviral Drugs Market Report 2030 is an in depth study analyzing the current state of the Antiviral Drugs Market. It provides brief overview of the market focusing on definitions, market segmentation, end-use applications and industry chain analysis. The study on Antiviral Drugs Market provides analysis of global market covering the industry trends, recent…
Antiviral Drugs Market
“Antiviral Drugs Market” study by “The Insight Partners” provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.
This Report encloses comprehensive analysis on the market and are assessed through volume and value data validated on three approaches including top companies revenues. It concludes with precise and authentic market…
Antiviral therapies Market: High Cost of Antiviral therapies Is a Major Restrain …
Post COVID-19 Impact on Antiviral Therapies Market –With the emergence of the COVID-19 crisis, the world is fighting a health pandemic as well as an economic emergency, almost impacting trillions of dollars of revenues. Research Dive’ group of skilled analysts provide a solution to help the companies to survive and sustain in this economic crisis. We support companies to make informed decisions based on our findings resulting from the comprehensive…
Increasing Utilization of Antiviral Drugs, During the COVID-19 Outbreak, to Prom …
According to antiviral therapies market analysis by Research Dive, the global market forecast will surpass $66,016.5 million in 2027, growing at a 3.1% CAGR from $51,913.1 million in the year2019.
Antiviral Therapies Market, COVID-19 Impact:
The global antiviral therapies market has responded positively to the pandemic owing to rise in the utilization of antiviral drugs in the development of effective medicines for the COVID-19 treatment. In addition, leading players in the global…
Coronavirus's Impact On Antiviral Packaging Market
Antiviral Packaging Market – An Overview
The coronavirus pandemic keeps on revamping the idea of worldwide society in 2020, and with it changes the perspectives and practices of buyers now and for a long time to come. In any case, the prompt effect on buyers’ interests about viral introduction and questions hanging about the infection’s capacity to make due on surfaces, may fuel an any longer enduring interest for new bundling…
Magniflex Introduces Antiviral and Antibacterial Collection
Magniflex, the renowned mattress manufacturer from Italy, has always had innovation in its DNA, as the success, accolades, and certifications obtained over the years prove, and the goal has always been to introduce innovative solutions to common issues that affect the quality of our sleep. As a response to the COVID-19 global pandemic, Magniflex conducted scientific and technological research in collaboration with prominent experts in order to produce MagniProtect: an…
